Johm Haanen, head of Cancer Immunotherapy The Netherlands Cancer Institute, summarizes his talk at the First VHIO BBVA Foundation Symposium.
Негізгі бет Learning from TIL to develop next generation cell therapies
Johm Haanen, head of Cancer Immunotherapy The Netherlands Cancer Institute, summarizes his talk at the First VHIO BBVA Foundation Symposium.
Пікірлер